Global Ganja Report

It has been a long, slow ride for patients hoping to get access to medical marijuana in the Lone Star state—and then just special strains of low-THC cannabis, and only for those suffering from "intractable epilepsy." Three dispensaries are hoping to get final approval from Texas authorities to start cultivating next month. Of course, it will be several more months before they can actually begin distributing—and then ambiguities in the law may mean further delays. Activists and lawmakers are pushing both to clear things up and expand the scope of the program.

Hemp Business Journal reports that products infused with CBD oil are leading growth in hermp-derived products sold in the United States generally, which in 2016 had a collective retail value of $688 million. This figure represents a five year 22% compound annual growth rate (CAGR). Joining more traditional products such as shelled seed, protein powder, soaps and lotions, are growing lines of medicinal preparations such as CBD edibles. Hemp-derived cannabidiol (CBD) accounted for $130 million in sales last year.

Oops, he did it again. Acting Drug Enforcement Administration chief Chuck Rosenberg reiterated his oft-voiced opinion on May 25 that "marijuana is not medicine." The Washington Examiner reports that he told an audience at a clinic in Cleveland: "If it turns out that there is something in smoked marijuana that helps people, that's awesome. I will be the last person to stand in the way of that... But let's run it through the Food and Drug Administration process, and let's stick to the science on it."

Here's some counterintuitive news for those who have been hammered all their lives with claims that cannabis causes memory loss. A new study by scientists at the University of Bonn, written up in the journal Nature Medicine, finds that aging mice treated with daily small doses of THC actually experienced a reversal of cognitive decline. That is, they started doing better on cognitive tasks, such as going though a maze. The researchers foresee potential cannabis-based treatment to fend off dementia. "If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care then that is more than we could have imagined," said study leader Andras Bilkei-Gorzo.

Wisconsin became the latest state to pass a strictly limited semblance of a medical marijuana law on April 18 as the arch-conservative Gov. Scott Walker signed Senate Bill 10, allowing patients to receive cannabidiol (CBD) extract from a physician or pharmacy with a prescription. The law, already passed by both houses of the legislature, takes effect immediately. It passed the Senate with only one dissenting vote, pointing to widespread support for the measure in the Badger State.

China is to get its first company dedicated to research, development and marketing of medicinal products based on cannabidiol, or CBD. The firm, dubbed XiBiDi Biotechnology Co, is to operate out of Pudong Technology Park, part of the Shanghai Pilot Free-Trade Zone. It will initially offer hemp-derived CBD oil, as well as hemp-based foods and beverages, according to a press release from ChineseInvestors.com, or CIIX. The Chinese character "XiBiDi" is homophonic to "CBD" in English.

Rep. Tom Garrett (R-VA) on Feb. 27 announced the introduction of legislation aimed at decriminalizing cannabis at the federal level. The ambitiously named "Ending Federal Marijuana Prohibition Act of 2017" would actually take cannabis off the federal controlled substances list—leaving regulation up to the states, and essentually giving the herb the same status as alcohol and tobacco. The bill revives an effort frst launched in the Senate by Bernie Sanders in 2015.

A rather sensationalistic piece in the New York Times last month luridly headlined: "Drug 85 Times as Potent as Marijuana Caused a 'Zombielike' State in Brooklyn." Apparently, emergency medical technicians called to a "mass casualty event" in Brooklyn's Bushwick neighborhood reported multiple people at the scene, "all of whom had a degree of altered mental status that was described by bystanders as 'zombielike,'" according to a study published in the New England Journal of Medicine. Blood and urine samples drawn from eight of the 18 men hospitalized that day revealed they had taken a synthetic cannabinoid called AMB-FUBINACA, originally developed by the pharmaceutical company Pfizer, with the street names "AK-47" or "24 Karat Gold." It is said to be 85 times as potent as the main agent in natural cannabis, THC, or tetrahydrocannabinol.